Hot Safest Stocks To Watch For 2019

Our Long Idea reports aim to identify those firms that the market has overlooked and that, when analyzed beyond standard metrics, are significantly undervalued. These hidden gems provide excellent upside potential to any portfolio, with little downside risk.

In addition to individual Long Ideas, we provide Model Portfolios that provide well-screened lists of companies based on specific criteria such as return on invested capital (ROIC) or dividend yield. In 2016, we added two new Model Portfolios, Exec Comp Aligned With ROIC and Safest Dividend Yields, to go along with our longstanding Most Attractive & Most Dangerous Stocks Model Portfolio, which has a long history of outperformance.

Below presents the Long Idea highlights of 2016 and the performance of our new Model Portfolios.

Long Idea Highlights

It pays to read our Long Idea reports. In 2016, 10 out of our 15 Long Idea stock and mutual fund picks saw positive returns and 13 stocks outperformed the market (S&P 500). All told, the Long Idea stocks averaged a 9.9% return in 2016, which was slightly more than the S&P 500’s return of nearly 9.5%, thereby outperforming as a long portfolio. Some of the top picks can be seen in Figure 1 below.

Hot Safest Stocks To Watch For 2019: BorgWarner Inc.(BWA)

Advisors’ Opinion:

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close was BorgWarner Inc. (NYSE: BWA) which traded down about 6% at $48.55. The stock’s 52-week range is $40.00 to $58.22. Volume was roughly 3 million compared to the daily average volume of 1.4 million.

  • [By John Ballard]

    Shares of BorgWarner (NYSE:BWA) gained 17.8% in value last month, according to data provided by S&P Global Market Intelligence. The stock price stumbled toward the end of 2018 along with the broader market, but found its footing as most stocks began to rebound at the start of 2019. 

  • [By Stephan Byrd]

    Dean Investment Associates LLC decreased its position in shares of BorgWarner (NYSE:BWA) by 3.2% in the first quarter, Holdings Channel reports. The fund owned 90,394 shares of the auto parts company’s stock after selling 2,955 shares during the quarter. Dean Investment Associates LLC’s holdings in BorgWarner were worth $4,541,000 as of its most recent SEC filing.

  • [By Ethan Ryder]

    Gentex (NASDAQ:GNTX) and BorgWarner (NYSE:BWA) are both mid-cap auto/tires/trucks companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on BorgWarner (BWA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on BorgWarner (BWA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Safest Stocks To Watch For 2019: HCI Group, Inc.(HCI)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    HCI Group Inc. (NYSE: HCI), which primarily focuses on the property and casualty insurance business in Florida, was last seen down 1.4% at $40.17. Its 52-week range is $28.70 to $44.25.

  • [By Stephan Byrd]

    HCI Group (NYSE:HCI) and National General (NASDAQ:NGHC) are both finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Hot Safest Stocks To Watch For 2019: Cummins Inc.(CMI)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Cummins (CMI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Neha Chamaria]

    Cummins Inc. (NYSE:CMI) is recalling 500,000 trucks to fix defects in emissions-control systems. This news seemed to have overshadowed a strong set of second-quarter numbers that the company released around the same time, roughly three weeks ago, capping potential upside in the stock. Cummins shares still are down about 19% year to date, as of this writing.

  • [By Stephan Byrd]

    Cummins Inc. (NYSE:CMI) – Oppenheimer dropped their FY2018 earnings estimates for shares of Cummins in a report released on Wednesday, August 1st. Oppenheimer analyst N. Kaye now expects that the company will post earnings of $14.10 per share for the year, down from their previous estimate of $14.54. Oppenheimer currently has a “Outperform” rating and a $192.00 price target on the stock.

  • [By Stephan Byrd]

    Cummins (NYSE:CMI) announced that its Board of Directors has approved a share repurchase program, which authorizes the company to buyback $2.00 billion in shares on Tuesday, October 9th. This buyback authorization authorizes the company to repurchase up to 8.3% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Hot Safest Stocks To Watch For 2019: Evoke Pharma, Inc.(EVOK)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Here are some of the news stories that may have impacted Accern’s rankings:

    Get Evoke Pharma alerts:

    Evoke Pharma (EVOK) Given a $9.00 Price Target by HC Wainwright Analysts (americanbankingnews.com) Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA (zacks.com) FDA to Review Gimoti for Diabetic Gastroparesis in Adult Women (empr.com) Evoke Pharma’s Gimoti™ NDA Accepted for FDA Review (finance.yahoo.com)

    Shares of NASDAQ EVOK traded up $0.08 during mid-day trading on Friday, reaching $2.44. 56,399 shares of the company’s stock were exchanged, compared to its average volume of 83,661. The stock has a market cap of $42.58 million, a PE ratio of -2.94 and a beta of 1.46. Evoke Pharma has a 52-week low of $1.85 and a 52-week high of $4.09.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *